IMMP News and Press, Immutep Limited From 10/31/23

Media Release Excellent survival benefit in 1st line non-small cell lung cancer (1L NSCLC) in TACTI-002 trial: median Overall Survival of 35.5 months (TPS ≥1% patients) providing additional 12-18 months survival compared to historical data, reported post period Late-stage &...

2023-10-25 08:49:17 ET More on Immutep Seeking Alpha’s Quant Rating on Immutep Historical earnings data for Immutep Financial information for Immutep For further details see: Immutep receives about A$1.13M R&D tax incentive from Australian govt

Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Austral...

Media Release Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer continues Strong 71.4% Overall Response Rate, 90.5% Disease Control Rate, 10.1-month median ...

Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS > 1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with hi...

Media Release New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CEST Immutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT ...

Uni Charm Corporation ADR (UNICY) is expected to report for Q2 2023 Clarus Therapeutics Hldgs (CRXTQ) is expected to report for quarter end 2023-06-30 Bed Bath & Beyond Inc. (BBBYQ) is expected to report for Q2 2024 CalAmp Corp. (CAMP) is expected to report $-0.04 for Q2 2024 ...

Media Release SYDNEY, AUSTRALIA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today anno...

Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...

Media Release SYDNEY, AUSTRALIA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today ...